Gelteq Limited (NASDAQ:GELS) stock is trading lower on Friday. The stock is experiencing a stark pullback following a period of extreme volatility. On Thursday, GELS shares skyrocketed by nearly 200%, making it a prime target for profit-taking.
The downward price action on Friday reflects a classic post-rally comedown. This sharp reversal highlights the volatile nature of micro-cap biotechnology stocks following explosive momentum sessions.
Veterinary Palatability Trials Prove Successful
The stock decline occurs despite positive operational news released by the company on Friday. Gelteq announced the successful completion of its veterinary palatability trials.
The company conducted these trials in collaboration with Kemin Industries, a leading U.S.-based global ingredient manufacturer.